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Abstract
Background: Respiratory distress syndrome (RDS) is the most common cause of respiratory failure in preterm
infants. Treatment consists of respiratory support and exogenous surfactant administration. Commonly, surfactant is
administered intratracheally. However, this requires airway instrumentation and subsequent fluid instillation which
may be harmful. Surfactant nebulization (SN) may offer a safe and effective alternative for surfactant administration,
but the clinical efficacy is not yet established. Thus, this systematic review and meta-analysis of randomized
controlled trials will summarize the available evidence to determine the effectiveness and safety of SN for the
prevention of intubation and subsequent mechanical ventilation at 72 h after birth.
Methods: A systematic literature search in Medline, Embase, and The Cochrane Library will be performed, and all
randomized controlled trials (RCTs) and quasi-RCTs from published articles, presentations, and trial registries will be
included in this meta-analysis. Titles and abstracts of all records identified in the search will be screened by two
reviewers independently.
Data on preterm infants (≤ 37 weeks) receiving nebulized surfactant in the first 72 h after birth for the treatment or
prevention of RDS will be evaluated. Primary outcome is the intubation rate by 72 h after birth, and secondary
outcomes include peridosing safety effects as well as major neonatal morbidities.
Risk of bias will be assessed using the revised Cochrane ROB tool, and subgroup analyses will be performed to
evaluate potential confounding factors. Publication bias will be assessed by examining a funnel plot. The meta-
analysis will be performed using a fixed-effects model.
Discussion: This review will provide an evidence-based tool for information about surfactant nebulization,
illustrating the current knowledge and hopefully revealing potential novel avenues for researchers and clinicians
alike.
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Depending on the level of prematurity, approximately
50–90% of very preterm infants with a gestational age
below 32 weeks at birth suffer from respiratory distress
syndrome (RDS) [1, 2]. Respiratory distress syndrome is
the most common cause of respiratory failure in preterm
infants. It is related to a primary surfactant deficiency
leading to an unphysiologically high pulmonary resist-
ance, increased work of breathing, and ultimately, higher
pressures needed for mechanical ventilation [1]. This in
turn can lead to epithelial lesions, the formation of hya-
line membranes, increased inflammation and ultimately
to the development of bronchopulmonary dysplasia
(BPD) [3, 4].
Treatment consists of respiratory support and exogen-
ous surfactant administration. Current neonatal resusci-
tation guidelines advise to stabilize preterm infants on
continuous positive airway pressure (CPAP) initially and
administer surfactant as early rescue therapy < 2 h after
birth, but only if respiratory compromise is suspected [5,
6]. While the benefit of surfactant has been widely inves-
tigated, the best route of surfactant application is not yet
determined [7–11]. Surfactant is commonly instilled into
the trachea, either by endotracheal intubation and subse-
quent mechanical ventilation or by inserting a nasogas-
tric tube into the trachea and removing it immediately
after instillation (MIST, minimally invasive surfactant
therapy). MIST may reduce volutrauma and airway in-
flammation [12–14]. However, there is still the need for
instrumentation of the airway and fluid instillation into
the trachea. Instrumentation of the airway is uncomfort-
able and painful for the preterm infant and may carry
the risk of concomitant vasovagal reactions and
pharyngeal/laryngeal injury. Furthermore, surfactant in-
stillation into the trachea leads to disruption of the cere-
bral blood flow and mean arterial blood pressure [15].
Additionally, intratracheal surfactant administration and
mechanical ventilation are associated with the develop-
ment of intraventricular hemorrhage [16–18].
In recent years, there has been an increasing shift to-
wards less invasive treatment options for RDS in pre-
term infants. Thus, a truly noninvasive approach for
surfactant administration which avoids clinical instability
and allows for repeated surfactant applications is still
needed. Surfactant nebulization (SN) may offer such an
alternative as it may be helpful in avoiding the need for
mechanical ventilation or instrumentation of the upper
airways [19].
Animal data
There is various animal data supporting the application
of SN: Nebulized surfactant improved lung compliance
and oxygenation in preterm lambs when compared to
saline nebulization [20]. In rabbits, surfactant nebuliza-
tion led to a more homogeneous surfactant distribution
when compared to instillation [21]. Further studies
showed reduced inflammatory markers when comparing
SN + CPAP to CPAP alone and demonstrated reduced
adverse hemodynamic effects of SN compared with
intratracheal surfactant instillation [15, 22–27]. Further-
more, SN has been shown to improve cerebral oxygen
metabolism when compared with intratracheal surfac-
tant bolus administration [27]. The clinical efficacy of
SN in animal studies was similar to intratracheal surfac-
tant application in improving the oxygenation index, the
arterial oxygen and carbon dioxide partial pressure as
well as the ventilation efficacy index [28].
Clinical data
While animal data show promising effects of SN, clinical
results to date are ambiguous and scarce [19]. There is
no single large trial evaluating the efficacy of surfactant
nebulization but various smaller studies with varying re-
sults [29–33]. Surfactant nebulization was associated
with a drop in partial carbon dioxide pressure [29] and
with a decreased required inspiratory fraction of oxygen
[32]. In other studies, there was no clinical benefit for
infants receiving SN [30, 31]. Therefore, this systematic
review and meta-analysis will assess the efficacy of SN
by combining studies of high methodological rigor and
will potentially reveal relevant factors associated with a
higher or lower efficacy.
Research question
This systematic review and meta-analysis of randomized
controlled trials will aim to evaluate the effectiveness of
SN in preterm infants with RDS. More specifically, this
review tries to answer the question whether surfactant
nebulization is effective in decreasing intubation rate by
72 h after birth in preterm infants with RDS (≤ 37 weeks
gestational age), when compared with standard care or
other forms of surfactant application.
Methods
The present protocol has been registered in the PROS-
PERO database (registration number (CRD42020175625)
and is being reported in accordance with the reporting
guidance provided in the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses Protocols (PRIS
MA-P) statement [34] (see checklist in Additional file 1).
Searches
A systematic literature search will be conducted on the
following electronic databases: Medline, Embase, and
The Cochrane Library [Cochrane Database of Systematic
Reviews, Cochrane Central Register of Controlled Trials
(CENTRAL)]. In addition, we will seek registered details
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of selected trials in the US National Institutes of Health
resource ClinicalTrials.gov. We will obtain information
by personal communication with the corresponding au-
thors and will review the reference lists of relevant arti-
cles, abstracts, and conference proceedings (Pediatric
Academic Societies, Society for Pediatric Research, Euro-
pean Society for Pediatric Research 1990–2019). There
will be no language restrictions. The searches will be re-
run just before the final analyses and further studies re-
trieved for inclusion.
We will search the electronic databases mentioned
above using stringent search terms, e.g., the following
for EMBASE:
((‘prematurity’/exp OR ‘infant’/exp OR prematur*:ti,ab
OR preterm*:ti,ab OR newborn*:ti,ab ORinfant*:ti,ab OR
neonat*:ti,ab) AND (‘lung surfactant’/exp OR ((surfac-
tant NEAR/5 (nebuli* ORaerosoli* OR administ*)):ti,ab))
NOT ([animals]/lim NOT [humans]/lim)) AND (‘cross-
over procedure’:de OR ‘double-blind procedure’:de OR
'randomized controlled trial’:de OR’single-blind proced-
ure’:de OR random*:de,ab,ti OR factorial*:de,ab,ti OR
crossover*:de,ab,ti OR((cross NEXT/1 over*):de,ab,ti) OR
placebo*:de,ab,ti OR ((doubl* NEAR/1 blind*):de,ab,ti)
OR((singl* NEAR/1 blind*):de,ab,ti) OR assign*:de,ab,ti
OR allocat*:de,ab,ti OR volunteer*:de,ab,ti)
Types of study to be included
We will include all randomized controlled trials (RCTs) and
quasi-RCTs. We will take into account the level at which
randomization occurred, including cross-over trials, cluster-
randomized trials, and multiple observations for the same
outcome. All animal studies will be excluded from analysis.
We will extract relevant data published in journals as well as
data only available in online clinical trial registries to perform
a meta-analysis and evaluate whether there is a significant
benefit of nebulized surfactant in preventing intubation and
subsequent mechanical ventilation at 72 h after birth.
Condition or domain being studied
This systematic review will summarize the available evidence
from randomized controlled trials to determine the effective-
ness and safety of SN for the prevention of intubation and
subsequent mechanical ventilation at 72 h after birth.
PICO: participants–intervention–comparator–outcome
Participants: Preterm infants (≤ 37 weeks) with RDS in
the first 72 h after birth
Intervention: Nebulized surfactant administration for
the prevention or treatment of RDS during the first 72 h
after birth
Comparator/control: Any control group will be in-
cluded. Thus, surfactant nebulization could be compared
to no treatment, to CPAP alone, or to a more invasive
surfactant administration method.
Outcomes:
– Primary outcome: intubation rate by 72 h after birth
– Secondary outcomes by timepoint:
 Peridosing events:
 Number of bradycardias ≤ 80 bpm during
nebulization measured by electrocardiography
or pulse oximetry
 Number of desaturations ≤ 80% FiO2 during
nebulization measured by pulse oximetry
 Vomiting during nebulization
 During or within the first 72 h after SN:
 Oxygen saturation and arterial carbon dioxide
levels at 1, 2, and 3 h after SN when compared
with baseline at the beginning of SN
 SpO2/FiO2 ratio at 1 h, as well as at 24, 48,
and 72 h after SN when compared with
baseline at the beginning of SN
 Mean airway pressure level at 1 h, as well as at
24, 48, and 72 h after SN when compared with
baseline at the beginning of SN
 Electrolyte imbalances (e.g., increase/decrease
in sodium, potassium, calcium, or chloride
levels 24 h after SN when compared with
baseline at the beginning of SN)
 Until 36 weeks postmenstrual age
 Blood-culture positive neonatal sepsis before
36 weeks postmenstrual age
 Pneumothorax or pulmonary interstitial
emphysema
 Severe intraventricular hemorrhage (grade 3
or 4 based on the Papile criteria [35])
 Any stage retinopathy of prematurity based on
the International Classification of Retinopathy
of Prematurity (2005) [36]
 Necrotizing enterocolitis (stage 2 or higher
according to the Bell classification) [37]
 Pulmonary hemorrhage
 At 36 weeks postmenstrual age:
 Number of days on mechanical ventilation
during hospitalization
 Intubation rate during hospitalization (i.e.
number of infants who were intubated at any
time during hospitalization)
 Death
 Moderate to severe BPD (defined as oxygen
requirement at 36 weeks postmenstrual age)
 At 18–24 months corrected age:
 Neurodevelopment, i.e., number of
infants with a Bayley-III composite
motor or cognitive score of more than
two SD below the mean (Bayley Scales
of Infant and Toddler Development,
third edition [38])
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Study selection and data extraction
Two reviewers will independently screen the titles and
abstracts of all records identified in the search and ob-
tain full texts of the relevant trials. The full texts will be
assessed, and those studies that do not meet all of the
inclusion criteria will be excluded. Any disagreements
will be discussed until consensus is achieved, if necessary
through referral to a third reviewer. Records of ineligible
full-text articles along with the reason for ineligibility
will be saved for future reference. We will contact au-
thors of primary studies to provide any missing informa-
tion every month for three consecutive months.
Risk of bias (quality) assessment
The risk of bias (ROB) of eligible studies will be assessed
according to the Revised Cochrane risk-of-bias tool for
randomized trials (RoB 2) [39]. The six criteria to be
assessed are sequence generation, allocation conceal-
ment, blinding of participants, personnel and outcome
assessors, completeness of follow-up, selective outcome
reporting, and presence of other biases. Each domain
will be assigned a score “definitely low risk” or “definitely
high risk” or “unclear risk”. We will further categorize
the “unclear risk” into “probably low risk” or “probably
high risk”. The confidence in the estimates for each out-
come will be assessed using the GRADE (Grading of
Recommendations Assessment, Development and Evalu-
ation) approach. We will assess reporting and publica-
tion bias by examining the degree of asymmetry of a
funnel plot.
Heterogeneity and subgroup analysis
We propose the following potential sources of clinical
heterogeneity, which could be possible effect modifiers:
gestational age, birth weight, surfactant dose, timing of
surfactant, type of nebulizer, type of surfactant, and fre-
quency of nebulization. We hypothesize that a lower
gestational age and a lower birth weight will be related
to a better effectiveness of SN. Furthermore, we specu-
late that a higher surfactant dose and more frequent ap-
plications lead to a better outcome and that different
types of nebulizer show different effectiveness. Addition-
ally, there are potential methodological sources of het-
erogeneity such as risk of bias, study design, publication
bias, or type of randomization. Sensitivity analysis will
be conducted including only the high-quality studies
(with “low” or “probably low” risk of bias) if possible.
Meta-regression models will assume a single shared
coefficient for all non-baseline treatments [40]. Inter-
pretation of meta-regression models will be in keeping
with recent suggestions, namely, inclusion of the coeffi-
cient leads to a decrease in the estimate of between-
study variance [40]. A meta-regression will be conducted
exploring the effect of the proposed sources of
heterogeneity on the effectiveness of SN depending on
availability of data.
Strategy for data synthesis and measures of treatment
effect
Data will be analyzed as aggregate. Effect estimates along
with 95% compatibility intervals (CIs) will be primarily
presented using risk ratios (RRs). Odds ratios (ORs) will
be reported as a supplementary analysis to account for
potential distortion of the RRs. The meta-analysis will be
performed using a fixed-effects model.
Discussion
This systematic review and meta-analysis will summarize
the available evidence from randomized controlled trials
to determine the safety and effectiveness of SN for the
prevention of intubation and subsequent mechanical
ventilation at 72 h after birth.
The last Cochrane review on the effectiveness of SN
was performed in 2012 and included a single random-
ized controlled trial [41]. There have been further re-
views of clinical data over the past years [19, 23, 42].
However, a recent randomized controlled trial examin-
ing the effectiveness of SN was not included so far [33],
and several more studies with a higher sample size are
about to be published (e.g., NCT03058666,
NCT03235986). Also, all the aforementioned reviews in-
cluded only studies published in journals while disre-
garding studies where results are only available in online
trial registries. The results of this systematic review and
meta-analysis will be of interest to a broad range of neo-
natologists, pediatricians, and researchers. Most import-
antly, it will show avenues of further research and
possible clinical applications to further improve nonin-
vasive RDS therapy in preterm infants which is of ut-
most importance in preventing associated long-term
impairments.
Our review will have several strengths. First, we will
implement a wide comprehensive search to include pub-
lished as well as thus far unpublished clinical trials. Sec-
ond, we will provide all-encompassing information on
all studies currently available and thus increase the in-
formative value of this review for clinicians and re-
searchers. Third, we will primarily focus on clinically
relevant outcomes such as intubation and mechanical
ventilation which are among the major risk factors asso-
ciated with the development of BPD. On the other hand,
the chosen primary outcome is a short-term clinical out-
come while long-term neurodevelopmental outcomes
may be more important to patients, parents, and care-
givers. However, we are not aware of any trial assessing
the efficacy of SN in reducing death and/or major neu-
rodevelopmental impairment. Also, it is known that in-
tubation in general as well as the duration of mechanical
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ventilation is associated with the development of BPD
[43], while BPD itself is associated with a worse neuro-
developmental outcome [44]. Thus, our approach may
yield clinically relevant results which may provide the ra-
tionale and background information to conduct a larger
trial focusing on long-term outcomes. Also, we included
death and major neonatal morbidities as secondary out-
comes to assess whether the smaller trials that have been
conducted to date may show a combined impact on any
of the longer-term outcomes.
We anticipate some challenges while undertaking such
a review. Over the last years, many new devices for sur-
factant nebulization have been conceived and built in
order to increase the amount of surfactant reaching the
lower airways, thereby aiming to improve clinical effi-
cacy [45–47]. Thus, we anticipate some degree of clinical
heterogeneity as we are considering different devices but
also different timepoints of application and a wide range
of gestational ages.
To summarize, we hope that this review will provide
information about surfactant nebulization with a high
level of evidence, illustrating the current knowledge and
hopefully revealing potential novel avenues for re-
searchers and clinicians alike. The findings of this review
may lead to the design of adequately powered trials
assessing longer-term outcomes and ultimately to an im-
proved medical care of this vulnerable population.
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